Timber pharmaceuticals reports positive top-line results from phase 2b control study evaluating tmb-001 in moderate to severe congenital ichthyosis

Basking ridge, nj, oct. 07, 2021 (globe newswire) -- via  newmediawire -- timber pharmaceuticals, inc. ("timber" or the “company”) (nyse american: tmbr), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced positive top-line data from its phase 2b control study evaluating tmb-001, an investigational topical isotretinoin formulated using timber's patented ipeg™ delivery system, in patients with moderate to severe congenital ichthyosis (ci).
TMBR Ratings Summary
TMBR Quant Ranking